Multiple Myeloma Market Trends & Growth Forecast 2025-2033
The Global Multiple Myeloma Market reached US$ 22.3 billion in 2024 and is expected to reach US$ 34.58 billion by 2032, growing at a CAGR of 5.6% during the forecast period 2025-2033.
Multiple Myeloma Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/multiple-myeloma-market?sz
The Multiple Myeloma market focuses on the diagnosis and treatment of this blood cancer affecting plasma cells, with therapies including immunomodulators, monoclonal antibodies, and CAR-T cell therapy. Driven by rising prevalence, advancements in targeted therapies, and ongoing clinical trials, the market is expanding. However, challenges such as high treatment costs and disease relapse remain significant concerns.
List of the Key Players in the Multiple Myeloma Market:
Amgen Inc., Sanofi, Novartis AG, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, ONO PHARMACEUTICAL CO., LTD., Pfizer Inc., Karyopharm and Amneal Pharmaceuticals LLC. among others.
Industry Development:
April 2024: Bristol Myers Squibb (BMS) and 2seventy bio, Inc. secured FDA approval for ABECMA (idecabtagene vicleucel) as a treatment for adult patients with relapsed or refractory multiple myeloma. This approval applies to patients who have undergone at least two prior lines of therapy, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody.
March 2024: Kite, a Gilead Company, and Arcellx, Inc. announced key operational updates for their anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel stands out as the first BCMA CAR T-cell therapy in multiple myeloma that features Arcellx's innovative D-Domain binder technology.
March 2023: Natco Pharma Ltd expanded its portfolio in the US by launching additional strengths of its generic lenalidomide capsules, a treatment for multiple myeloma. In partnership with Teva Pharmaceuticals, the company introduced 2.5 mg and 20 mg doses of the generic version of Revlimid (lenalidomide capsules).
Growth Forecast Projected:
The Global Multiple Myeloma Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
Research Process:
Both primary and secondary data sources have been used in the global Multiple Myeloma Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/multiple-myeloma-market
Segment Covered in the Multiple Myeloma Market:
By Type: Smoldering (Indolent) Multiple Myeloma, Active (Symptomatic) Multiple Myeloma.
By Treatment: Chemotherapy, Immunotherapy, Radiation, Stem Cell Transplant, Targeted Therapy.
By End-User: Hospitals, Cancer Centers, Others.
Regional Analysis for Multiple Myeloma Market:
The regional analysis of the Multiple Myeloma Market covers key regions including North America, Europe, Asia Pacific Middle East and Africa and South America. The North America with a focus on the U.S., Canada, and Mexico; Europe, highlighting major countries like the U.K., Germany, France, and Italy, along with other nations in the region; Asia-Pacific, covering India, China, Japan, South Korea, and Australia, among others; South America, with emphasis on Colombia, Brazil, and Argentina; and the Middle East & Africa, which includes Saudi Arabia, the U.A.E., South Africa, and other countries. This comprehensive regional breakdown helps identify unique market trends and growth opportunities specific to each area.
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Benefits of the Report:
➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.
➡ Top-down and bottom-up approach for regional analysis
➡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.
➡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market
Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/multiple-myeloma-market
Browse More Reports: https://www.datamintelligence.com/research-report/multiple-myeloma-market
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian